D P Wigington

Summary

Publications

  1. ncbi request reprint Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines
    D P Wigington
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 24:2905-12. 2004
  2. ncbi request reprint Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells
    D P Wigington
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 25:1909-17. 2005
  3. ncbi request reprint Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug
    Y R Wang
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 25:4333-9. 2005

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines
    D P Wigington
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 24:2905-12. 2004
    ..1,24(S)-Dihydroxyvitamin D2 [1,24(OH)2D2] is a naturally occurring active vitamin D compound with low calcemic activity...
  2. ncbi request reprint Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells
    D P Wigington
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 25:1909-17. 2005
    ..1,24(S)-dihydroxyvitamin D2 [1,24(OH)2D2] is a naturally occurring active vitamin D compound with high antiproliferative activity and low calcemic response...
  3. ncbi request reprint Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug
    Y R Wang
    Bone Care International, 1600Aspen Commons, Middleton, WI 53562, USA
    Anticancer Res 25:4333-9. 2005
    ..These synergistic interactions suggest the potential clinical utility of 27-OH-BCI-210 in the treatment of prostate and breast tumors...